Base Editing Therapy Shows Universal Efficacy in Blood Disorder Trials

Researchers from CorrectSequence Therapeutics, in collaboration with international institutions, have successfully extended their base-editing therapy to a diverse patient cohort from Nigeria, Laos, Malaysia, and Pakistan. The study, which follows earlier success in Chinese transfusion-dependent β-thalassemia patients, demonstrates that CS-101 and CS-206 therapies achieve rapid hematopoietic reconstitution and sustained hemoglobin expression without the risks associated with traditional nuclease-based methods.

The clinical data highlights the precision of the tBE platform, which avoids DNA double-strand breaks by converting bases directly. In the case of a 21-year-old Nigerian patient with sickle cell disease, the treatment eliminated vaso-occlusive crises for 15.5 months, with hemoglobin levels rising from 7.7 g/dL to over 11 g/dL. Similarly, three patients with β-thalassemia achieved complete transfusion independence. Comparative analysis indicates that tBE facilitates faster neutrophil and platelet engraftment and higher fetal hemoglobin levels than Cas9 or Cas12a-based therapies.

Professor Chen Jia, founder of Correctseq, noted that these results confirm the platform's ability to transcend varied genetic backgrounds. With over 30 patients treated globally, the company is now preparing to apply its proprietary editing systems to address metabolic and cardiovascular conditions, including hypertriglyceridemia and homozygous familial hypercholesterolemia.